<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03242278</url>
  </required_header>
  <id_info>
    <org_study_id>18733</org_study_id>
    <secondary_id>XA1511US</secondary_id>
    <nct_id>NCT03242278</nct_id>
  </id_info>
  <brief_title>Real-world Dosing Patterns of Rivaroxaban in the United States</brief_title>
  <official_title>Real-world Dosing Patterns of Rivaroxaban in the United States (RIVA-D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the proportion of Non-valvular atrial fibrillation (NVAF)
      patients receiving the standard dose of 20 mg of rivaroxaban or the reduced dose of 15 mg of
      rivaroxaban.

      The secondary objective is to determine if dosing patterns for rivaroxaban may be influenced
      by baseline chronic kidney disease (CKD) status (as a proxy for measured baseline renal
      function).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2016</start_date>
  <completion_date type="Actual">March 1, 2016</completion_date>
  <primary_completion_date type="Actual">March 1, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of NVAF patients receiving 20 mg Rivaroxaban</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of NVAF patients receiving 15 mg Rivaroxaban</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline renal function</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">12507</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>NVAF patients receiving 20 mg rivaroxaban</arm_group_label>
    <description>NVAF patients who receive a standard dose of rivaroxaban (20 mg daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVAF patients receiving 15 mg rivaroxaban</arm_group_label>
    <description>NVAF patients who receive a reduced dose of rivaroxaban (15 mg daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939)</intervention_name>
    <description>As prescribed by treating physicians</description>
    <arm_group_label>NVAF patients receiving 20 mg rivaroxaban</arm_group_label>
    <arm_group_label>NVAF patients receiving 15 mg rivaroxaban</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with non-valvular atrial fibrillation (NVAF)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NVAF (non-valvular atrial fibrillation) will be defined as the occurrence of 2 or more
             inpatient or outpatient claims with International Classification of Disease ICD-9
             427.31 as the diagnosis code at any time in the patient's data history prior to
             inclusion

          -  Patients will be required to have 180 days of enrollment for the assessment of
             baseline characteristics

          -  CHA2DS2-Vasc score â‰¥2 during the 180 days prior to index rivaroxaban use baseline
             period

          -  Evidence of continuous enrollment in MarketScan during 180 days before the date of the
             first prescription of rivaroxaban

        Exclusion Criteria:

          -  Patients &lt;18 years of age

          -  Patients with valvular AF (atrial fibrillation)

          -  Pregnancy

          -  Malignant cancers

          -  Transient cause of AF

          -  Patients with VTE (Venous thromboembolism), pulmonary embolism or DVT (Deep Vein
             Thrombosis)

          -  Patients with major surgery defined as hip or knee replacement

          -  Prescriptions of OACs (Oral anticoagulants) (apixaban,warfarin, dabigatran,
             rivaroxaban) before index date

          -  Prescription of more than one OAC on the index date
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2017</study_first_submitted>
  <study_first_submitted_qc>August 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2017</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-valvular atrial fibrillation (NVAF)</keyword>
  <keyword>Prevention</keyword>
  <keyword>Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

